Hoth Therapeutics(US:HOTH) Prnewswire·2026-01-21 13:13Core Viewpoint - Hoth Therapeutics has received a key patent approval in China for its HT-KIT cancer program, which targets KIT signaling pathways to induce apoptosis in cancer cells, enhancing its intellectual property position in a significant oncology market [1][2][3]. Group 1: Patent Approval and Technology - The patent, originating from a PCT international application, provides essential intellectual property protection in China, a rapidly growing oncology market [2]. - HT-KIT is designed to disrupt aberrant KIT-driven signaling implicated in multiple cancers, utilizing splice-switching and molecular targeting strategies to trigger programmed cell death [3][4]. - The newly approved patent covers systems and methods for targeting KIT to induce apoptosis, reinforcing Hoth's strategy of developing precision oncology therapeutics [4]. Group 2: Strategic Importance of China - China is a critical jurisdiction for oncology intellectual property due to its expanding biopharmaceutical market and increasing oncology drug adoption [5]. - Patent protection in China may enhance future partnering, licensing, and strategic transaction opportunities related to HT-KIT [5]. - Hoth continues to convert its international patent filings into issued assets, a key value inflection point for biotech investors [6]. Group 3: Global Oncology IP Portfolio - The HT-KIT patent adds to Hoth's expanding portfolio of oncology and immunology assets, emphasizing the company's commitment to building long-duration shareholder value through IP-driven drug development [7]. - Hoth plans to advance HT-KIT while pursuing additional regulatory, development, and strategic milestones across its pipeline [7].